Navigation Links
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)
Date:6/4/2009

EXTON, Pa., June 4 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the baseline LaunchTrends(TM): SIMPONI report. The survey was completed by U.S. Rheumatologists in May 2009, just days after the FDA announced approval for SIMPONI (golimumab).

Once monthly dosing seems to be playing well, according to the Rheumatologists in the study who anticipate relatively quick uptake of SIMPONI. 84% of the Rheumatologists surveyed report that they intend to use SIMPONI within the next six months, and a fair proportion intend to incorporate SIMPONI into their armamentarium right away. The majority of RA patients likely to be placed on SIMPONI are expected to be switched from current biologic agents, primarily impacting use of Enbrel, Humira and Remicade. The main advantages that clinicians perceive for SIMPONI compared to currently available agents are the monthly dosing regimen and self injection. On the downside, SIMPONI is a new addition to an already crowded market of TNF agents with a similar mechanism of action and a lack of any clear clinical differentiation. Concern was also expressed about the lack of radiographic data at the time of launch to support the drug's ability to slow the progression of disease.

Adding to the competitive environment, the FDA approved UCB's CIMZIA(R) (certolizumab) for Rheumatoid Arthritis on May 14th, bringing yet another once monthly TNF agent into the mix. In addition to the recent launches of SIMPONI and CIMZIA there is significant interest among Rheumatologists in Roche's ACTEMRA(R) (tocilizumab), an IL-6 blocker currently under review with the FDA. When presented with all three products, interest was highest for ACTEMRA.

LaunchTrends(TM) measures launch effectiveness of new products from FDA approval through six months post launch. The next wave of this report, measuring uptake at one month post launch, will be fielded on June 22 and will be expanded to include CIMZIA in the competitive set. The results will be published in mid-July.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact Paul Callahan at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Announces Monthly Investor Conference Call
2. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. National Council on Disability Monthly Bulletin for February, 2009
4. U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6
5. Medical City Hospital Named by Texas Monthly as One of the Top Ten Best Companies to Work for in Texas
6. National Council on Disability Monthly Bulletin for November 2008
7. Renowned Thoracic Surgeon Recognized as Top Doctor by Peers in Annual New Jersey Monthly Magazine Survey
8. National Council on Disability Monthly Bulletin for October 2008
9. National Council on Disability Monthly Bulletin for June, 2008
10. National Council on Disability Monthly Bulletin for March 2008
11. National Council on Disability Monthly Bulletin for February, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using the ... can reconnect with America as it explores some of the best places to hike ... an inventive new place for a family vacation, and have discovered hiking. Many will ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: ... FAMILY-Our Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... used to say, he is "panther quick and leather tough." His love for others ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: ... many others. “Cactus Jack: Against All Odds” is the creation of published author, ... Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, ... most appropriate instruments for research and understanding the basic principles that were designed ... focus on innovations in stereo microscopy for brightfield and fluorescence typically used in ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017  The Corporate Whistleblower ... employees of sleep therapy clinics to call us ... therapy clinic is involved in a substantial scheme ... in hearing from an employee of a medical ... a kickback scheme to provide medical practice groups with ...
(Date:5/10/2017)... 10, 2017 CSSi, the global leader in ... research industry, is proud to announce the launch of ... website features both enriched content and a customized layout ... the company,s already well-established position as the top global ... "After many months of hard work, we are delighted ...
(Date:5/9/2017)... 9, 2017  Demonstrating its commitment to representing ... for the Pharmaceutical Research and Manufacturers of America ... companies will now have to meet new research ... eligible to join PhRMA. "By putting ... sending a clear message that being a member ...
Breaking Medicine Technology: